Apr 17 |
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)
|
Apr 10 |
Recce Pharmaceuticals Provides Business Update
|
Apr 10 |
Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024
|
Apr 4 |
Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives
|
Mar 22 |
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio
|
Mar 19 |
Recce Pharmaceuticals Completes Dosing Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|
Mar 14 |
Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
|
Mar 13 |
Recce Pharmaceuticals to Present at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) 2024 Annual Meeting
|
Mar 12 |
Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance
|
Feb 29 |
Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute
|